Index

Tables, figures, and case studies are indicated by appending “t”, “f”, or “c” to the page number. Contents of tables are not indexed separately.

A
absorption, distribution, metabolism and excretion (ADME)
gene therapy products, 330, 332
preclinical testing, 166–167
accelerated assessment
additional pathways for, 384–385
ATMPs, 316, 317t
CAT request for human tissues, 344
CHMP recommendation for, 35
conditional authorisation, 339
EMA advice meetings, 44t
EMA initiatives, 101
for orphan designation products, 384
prepandemic influenza vaccines, 360
procedures for, 339
registration of medicinal products, 211
regulatory mechanisms for, 3–4
requests for, 147
active pharmaceutical ingredients (API)
EDQM inspection process, 233
in generic products, 241
Active Substance Master File (ASMF)
with combination products, 396
generic medicinal products, 248
IGDRP work on, 248
MA dossier quality section, 144
medicinal product registration, 214
acute/repeat dose toxicity studies, 167
Ad Hoc Expert Group
MAA review, 54
meeting of, 56
adaptive and alternative pathways
accelerated access initiatives by EMA, 159–160
eligibility for, 159, 161f, 210
HTA/EMA collaboration for, 88–89
legal framework for, 160–162
medicinal products, 160–162
for orphan designation products, 385
principles of, 160
procedural guidance for, 162
product eligibility for, 161f
Advanced Therapy Medicinal Products (ATMPs)
authorised in EU, 319t
borderline and criteria precluding from, 321–324
certification of, 324
characterisation and quality control, 326
classification of, 320–321, 321t, 341–342
classification procedures for, 320–324
GTMP, 325–326, 328–330
legal framework, 344
MA procedures for, 344
pharmaceutical regulation evolution, 21–22
preclinical development, 329–330
product characterisation, manufacturing and quality
control of, 326–327
regulation, 315–334, 344
risk management for, 330–331
sCTMPs, 324–330
subcategories of, 316–317
summary, 331–332
supply without MA grant, 319–320
TEPs, 325, 327, 329–330
Adverse Drug Reactions (ADRs)/reporting
for biosimilar medicinal products, 265
defined, 177
Eudra Vigilance databases, 182, 265
Index

from healthcare professionals, 302
human blood or plasma products, 371
nonprescription medicinal products, 273
for paediatric product development, 100
PRAC activities for, 251
requirements of Member States, 250–251

advertising and promotion, 103–114
abbreviated ads as reminders, 106
comparative advertisements, 110
contents for HCPs, 105–106
EFPIA goals and code, 104–105
enforcement by competent authorities, 120
to general public, 108
general public content, 107–108
generic medicinal products, 253
HCPs, 105–106
to healthcare professionals, 105
healthcare professionals (HCPs), 105–107
Internet media, 109
jurisdictions for, 111–112
market surveillance, 110–111
medical devices, 112
nonauthorised products, 109–110
nonprescription medicinal products, 272–273
off-label information, 109–110
OTCs, 108
preapproval of material, 111–112
press releases, 108–109
regulatory framework, 103–104
regulatory strategy for, 138
sales representatives/sample distribution, 105–106
scientific service by MAA, 111
self-regulation, 104–105
American Association of Tissue Banks (AATB), 337
Anatomic, Therapeutic, Chemical Classification (ATC) code, 146
animal models
pharmacodynamic testing, 259–260
tissue-engineered product, 359
Annual Safety Reports (ASRs), 175

authorisation procedures for medicinal products
Centralised and Mutual Recognition Procedures for, 142–143
Centralised Procedure, 145–149
Decentralised Procedure, 151–153, 154t
eCTD format and acceptability, 145
legal framework for MAA, 142–143
MA dossier quality section, 144
MA system, 142–143
Mutual Recognition Procedure, 149–151
national authorizations, 153
Notice to Applicants (NTA) for medicinal products, 142–143
referrals, 156–157

B
Belgium
advertising preapproval, 111
BeNeLuxA, 23
bibliographic applications/well-established use, 155–156
bioequivalence, 242, 244–245
Biologics Working Party (BWP), 21, 368

biosimilar medicinal products
administration route and dosage parameters, 261
authorised active substance in, 258
clinical comparability demonstration for, 260–261
comparability to reference product, 258–259
cumulative development of, 263f
development processes for, 259f–260f
effects of change to reference product, 263
GLPs for, 260
immunogenicity testing for, 261
MAA data package for, 264t
MAA submission for, 261–262
pharmaceutical regulation evolution, 22
pharmacovigilance and safety reporting, 264
postapproval lifecycle management, 263–264
preclinical study program for, 259
registration of, 261–263
safety reporting for, 264–265
therapeutic interchangeability, 22, 263
timeline for development of, 261f
types of biological medicinal products, 257–258
urgent safety restrictions for, 264

biotechnology-derived products
accelerated assessment procedure, 279
centralised procedure for, 279–280
clinical information, 283
conditional authorisation, 279
development processes for, 258, 280
developmental pharmaceutics, 280
exceptional circumstances application procedure, 279
GLP for preclinical testing, 282–283
MA maintenance, 280
manufacturing information for, 281
pathways to marketing authorisation, 277–278
pharmacovigilance and safety reporting, 283
postapproval lifecycle comparability, 283
postapproval variations, 283
registration procedures for, 278–279
release testing in Europe, 282
TSE and viral clearance data for, 281–282

Blood Products Working Party (BPWP), 368

British Pharmacopoeia (BP), 237

C
carcinogenicity studies, 167
| central individual case study report (ICSR) | electronic submissions, 313 |
| in PMSF, 304 |
| processing center performance, 305 |
| submission and processing requirements, 307, 309, 309f |
| centralised marketing authorisation | MAA review for, 53–60 |
| medicinal products, 142–143 |
| Centralised Procedure (CP) | advantages and disadvantages for biotechnology products, 279, 283 |
| advantages/risk comparison for nonprescription medicines, 270t |
| application evaluation timetable for, 148t |
| ATMP MAA timetable, 345–347t |
| authorisation system, 20 |
| biosimilar medicinal product registration, 261, 265 |
| biosimilar medicinal products, 261 |
| biotechnology-derived product marketing authorisation, 271–272, 277 |
| Brexit effects for UK, 10 |
| combination products, 390 |
| comparison of pathways for nonprescription products, 270f |
| DNA and therapeutic vaccines, 361 |
| dossier assessment procedures, 218 |
| dossier requirements, 297 |
| eligibility request for generic medicinal products, 250 |
| EMA committee evaluation of products, 7, 14 |
| EMA presubmission guidance, 278 |
| evaluation of products, 14 |
| generic medicines, 243 |
| human blood/plasma product registration, 369 |
| human blood/plasma product renewal and pharmacovigilance, 371 |
| Information and Work Sharing projects, 250 |
| inspection process with, 230 |
| labelling and package leaflet (PL), 252 |
| MA issued under, 149 |
| MAA evaluation by EMA, 2 |
| MAA procedures, 145–147, 219f |
| medicinal product authorisation, 245 |
| medicinal product authorisation procedures, 145–149 |
| medicinal product clinical trials, 249 |
| for nonprescription medications, 269 |
| orphan medicinal products, 371 |
| pan-European generic authorisation, 255 |
| pan-European registration system, 19 |
| postauthorisation assessment procedure, 290 |
| pre-pandemic influenza vaccines, 360 |
| prescription to nonprescription reclassification, 271–272 |
| product criteria for use, 19, 151, 157, 278 |
| product exclusivity under, 155 |
| registration of medicinal products, 205, 208 |
| regulatory dossier assessment, 218 |
| scientific advice and parallel meeting for, 48 |
| vaccine licensure, 356 |
| variation assessment and notifications, 297–299 |
| certificate of analysis, 233, 354 |
| Certificate(s) of Suitability (CEP) | for APIs, 244 |
| EDQM issue of, 144, 216 |
| GMP inspections, 231–233 |
| registration of medicinal products, 216 |
| significance of, 233–234 |
| Chemical Abstracts Service (CAS) number, 169 |
| Clinical Effectiveness (EFF) HTA model, 80 |
| clinical investigations vs clinical trial definitions, 116 |
| Clinical Trial Application (CTA) | EU laws and regulations, 39 |
| vaccines, 354 |
| clinical trial authorisation process | application to national competent authority, 184 |
| Ethics Committee evaluation and Member State competent authority, 183–184 |
| Ethics Committee opinion application, 184 |
| GMO-based products, 327, 361–362 |
| Clinical Trials Directive (CTD), 174–176 |
| amendment of in-progress clinical trial, 187 |
| Annual Safety Reports (ASR) requirements of, 176 |
| application to IMPS, 179–181 |
| clinical trial end declaration, 187–188 |
| CTA process and authorisation process, 183–187 |
| declaring end of clinical trial, 187–188 |
| ECTR significant changes from, 178–179t |
| EudraCT changes, 182–183 |
| EudraPharm function, 183 |
| objectives and transition to ECTR, 174, 176 |
| serious adverse reaction (SAR) reporting, 177 |
| Clinical Trials Facilitation Group (CTFG), 177 |
| clinical trials for medicinal products, 173–204 |
| amendment notifications, 184–187 |
| biological product guidance, 354 |
| clinical trial application scientific assessment, 191f |
| clinical trial authorisation procedure, 190f |
| clinical trial regulatory telematics structure transitions, 181–182 |
| DSUR contents, 198t |
| ECTR and Clinical Trials Directive definitions, 180–181t |
| ECTR implementation | clinical trial application process, 188 |
| clinical trial authorisation, 188 |
| CTA dossier contents, 193f |
| EU Clinical Trials Register (EUCTR), 183 |
| EU Telematics, 181–182 |
Index

Part II CTA assessment, 192f
serious adverse event reporting, 196f

Coding Directive, 349

combination products, 389–398
borderline products, 391
conformity assessment requirements, 395
determination of registration pathway, 390
directives and guidance documents, 393–394
heparin and AIMD, 397c
IVDs and CDx, 396
labelling requirements, 397
medicinal product/device delineation, 389–390
pharmaceutical consultation procedure, 395–396
postmarket surveillance requirements, 397
product classification by PMOA, 390–393
quality system requirements, 396–397
regulatory classification determination, 394
set for local anaesthesia with lidocaine, 397–398c
sunblock cream/embedded barrier for vitiligo, 398c
in vitro fertilisation/transplant organs or tissue, 397c

combined ATMPs (cATMPs), 316, 320, 331

Committee for Advanced Therapies (CAT)
ATMP classification and certification by, 321t, 324, 341, 379
ATMP Regulation and, 317–321
combination products, 396
feedback during MA review, 54, 55f
MAA evaluation by, 344
MAA review, 53–54, 54t
PRAC advise to, 56
PRIME rapporteur appointment from, 36–37
rapporteur appointment from, 146, 294
representation in, 54
responsibilities of, 4, 8, 54t

Committee for Medicinal Products for Human Use (CHMP)
ATMP marketing authorisation, 344
conditional marketing authorisation grant, 35
GCP adoption by, 194, 309
human blood or plasma product regulation, 368, 377
inspection requests from, 230
MAA review, 53–54, 54t
meeting preparation timeline, 57f
PDCO appointments, 95
PRAC recommendation endorsements, 119
responsibilities of, 7

Committee for Medicinal Products for Veterinary Use (CVMP), 8, 230

Committee for Orphan Medicinal Products (COMP), 207
orphan designation request review, 38
rare disease designation review, 376
responsibilities of, 8, 207, 378
scientific advice from, 37, 48

Common European Submission Portal (CESP), 187–188

Common Technical Document (CTD)
biotechnology-derived product pharmaceutics, 280–281
eCTD envelope, 215–216, 216t
eCTD format and acceptability for medicinal products, 145
MAA EU format and content, 144–145
medicinal product registration, 215–216, 215t
for vaccines, 354

Communication and Tracking System (CTS) database, 152–153
community interest referral, 157
comparative matrix of legislation, 399–446
Competent Authorities for Medical Devices (CAMD), 116
Complete/Full and Independent application, 153
Concerned Member States (CMS)
application review timeline in, 186
authorisation of clinical trials under ECTR, 188–189
clinical trial acceptability, 188–189
clinical trial management and notifications, 192
clinical trial safety procedures, 187
clinical trials for medicinal products, 175
communications with Reference Member State, 219–220
decentralised procedure applications, 209
decentralised procedure referral, 157
decentralised procedures, 152, 219–220
dossier validation in, 218
DSUR submission, 197
IMPD cross-referencing, 194
inspection report submission by sponsor, 194
manufacture and importation, 252
MRP, 220–221
Mutual Recognition Procedure phase 2 timeline, 150
national law application in, 201
RMS evaluation for MA, 19
scientific advice for IMPs, 188
scientific advice from competent authority, 186
sponsor selection of, 209
vigilance procedures in, 342

conditional authorisation
accelerated assessment, 339
biotechnology-derived products, 279
by CHMP, 35
for orphan designation products, 384
registration of medicinal products, 210

conformity assessment in product development, 136
Cost and Economic Evaluation (ECO), 80
cost-based pricing (CbP model), 63–64
D
Danish Centre for HTA (DACEHTA), 78
Danish Promotion Code, 106
Decentralised Procedure (DCP)
applications to other Member States, 150
ATC code and, 146
biosimilar medicinal product registration, 261
biotechnology-derived product marketing authorisation, 277
CMDh, 8, 10
EU regulatory bodies for, 205
flow chart for, 154t
generic medicinal products, 245–246
human blood/plasma postmarket requirements, 371
human blood/plasma product registration, 369
Information and Work Sharing projects, 250
initial MAA, 220f
market access mechanism, 19, 143, 149, 151–153
medicinal product authorisation procedures, 151–153
medicinal product registration, 208–209, 219–220
nonprescription medicinal products, 269
pathways for nonprescription products, 270f
postauthorisation requirements for pharmaceuticals, 288
referrals, 157
regulatory dossier assessment, 219–220
variation assessment and notifications, 295, 297–298
Declaration of Helsinki, 175, 254
delegated act definition, 230
Description and Technical Characteristic of Technology (TEC) HTA model, 80
Development International Birth Date (DIBD), 197
Development Safety Update Report (DSUR)
contents of, 198t
EVCTM for submission, 199
format for, 307, 308t
ICH guideline for, 177, 196–197
ICH replacement for annual report, 176
Directive in legal framework, 230
Directorate- General for Health and Consumers (DG SANCO), 368
Directorate-General for Health and Food Safety (DG SANTE), 368
divergent decision referral, 157
Draft Assessment Report (DAR), 219
drug and biologic regulatory pathways
MAA, 32
product development, 31–32
drug product process validation scheme, 215–216
E
EMA meetings
advice meetings, 43–44t
CHMP meeting preparation timeline, 57f
communications for MAA, 41–52
core briefing materials for, 57–58
ever early preparation for, 57
face-to-face meetings, 54–56
general preparation for, 47–48
for MAA, 41–52
MAA procedural steps and, 42–47
during MAA review, 53–60
MAA review, 53–60
Q&A preparation, 58
rehearsals for, 59
rehearsals in Amsterdam, 59
representation and feedback from, 55f
scientific advice review, 48
Scientific committee role in, 53
scripting/developing core presentation, 58
slide development and management, 58–59
Standard Assessment Review Timeline, 55f
steps for preparation, 56–57
steps required for, 45t
timelines for, 46t
understand committee members, 57
written briefing document, 58
enforcement
CE marking errors, 117
Eudamed communications, 118
medicinal product advertising and promotion, 119–120
medicinal product GMP compliance, 119
medicinal product pharmacovigilance, 119
medicinal products recalls, 119
notified bodies, 118
Safeguard Clause, 117
Enpr-EMA, 101
Essential Requirements (ER)
legal documents, 18
safety and performance vs technical documentation, 23–24
Ethical Analysis (ETH) HTA model, 80–81
Ethics Committees (ECs)
application for opinion on clinical trial, 184
contents of application to, 185t
EU Clinical Trials Register (EUCTR), 183
EU In Vitro Diagnostics Regulation (EU IVDR), 138
EU laws and regulations
basic legislation for, 14
Clinical Trials Regulation (536/2014), 39
codification/clarification of pharmaceutical directives, 19
comparative matrix of legislation, 399–446
CTA, 38–39
current regulation evolution, 17–19
economic issues, 16–17
falsification and counterfeiting, 17
Index

General Data Protection Regulation (GDPR), 138
information availability and transparency, 16
IVDD, 26
medical device regulation evolution, 23–24
medical product regulation development, 14–15
orphan medicinal products (OMPs), 38
Paediatric Regulation, 121
patient advocacy and involvement, 16
pharmaceuticals regulation, 20
PRIME, 36–37
product innovation, 15–16
scientific advice and protocol assistance, 37–38
traditional herbal medicinal products, 23
unsafe product consequences, 15
EU MDR and EU IVDR
ATMPs, 344–348
human tissues, cells and derivatives, 348
EU Medical Device Regulation (EU MDR), 133–134, 344–345
EU regulatory affairs
adaptive and alternative pathways, 159–164
advertising and promotion, 103–114
ATMP regulatory framework, 315–334
biosimilar medicinal products, 257–266
combination products, 389–398
drug and biologic regulatory pathways, 31–40
EMA and other regulatory bodies, 1–12
enforcement and competent authorities, 115–120
Falsified Medicines Directive (FMD), 121–134
generic medicinal products, 241–256
Health Technology Assessment (HTA), 77–92
history of regulations, 13–30
human blood or plasma products, 365–374
human tissue regulation, 335–352
MAA for biotechnology derived products, 277–286
Marketing Authorisation Application (MAA) review, 53–60
Marketing Authorisation Application (MAA) submissions, 41–52
medicinal product authorisation procedures, 141–158
medicinal product clinical trials, 173–203
medicinal product registration procedures, 205–226
nonprescription medicinal products, 267–276
orphan medicinal products (OMPs), 375–388
Paediatric Regulation, 93–102
pharmaceutical postauthorisation requirements/compliance, 287–300
pharmaceutical quality systems and inspectorate process, 227–240
pharmacovigilance, 301–314
preclinical testing and GLP, 165–172
pricing and reimbursement, 61–76
regulatory strategy, 135–140
vaccines, 353–364
EU Tissue and Cell Directives (EUTCD), 335–337
EU Treaty, 14
Eudamed: competent authority communications, 118
EudraVigilance databases, 182
EudraCT paediatric clinical trial records, 183
EudraGMDP inspection information, 233
EudraVigilance Clinical Trial Module (EVCTM), 196, 199
EudraVigilance medicinal product dictionary (xE-VMPD), 304
EudraVigilance Postauthorisation Module (EVPM), 357
Eurasian Economic Union Member States, 238
European Association of Tissue Banks (EATB), 337
European Blood and Marrow Transplantation Group (EBMT), 337
European Clinical Trial Database (EudraCT)
clinical trial databases, 38, 100
SUSAR reporting, 182
European Clinical Trial Regulation (ECTR)
adverse reactions in, 177
application to IMPS, 179–181
electronic reporting, 183
EU Clinical Trials Register (EUCTR), 181–182
EU Portal, 181
EU portal and database, and associated legacy systems, 175
EU Telematics Strategy and Implementation Roadmap, 181
EudraVigilance Clinical Trial Module (EVCTM), 181–182
evaluation for duplication, 182
implementation guidance documents, 176–177
Member States national laws and, 175
significant changes from Clinical Trials Directive, 178–179t
European Commission (EC)
initiatives and models for pricing, 63–64
Notice to Applicants (NTA) for medicinal products, 142–143
regulatory authorities, pharmaceutical quality, 229
Task Force for Relations with the United Kingdom (UKTF), 228, 230
European community referral, 156
European Directory for the Quality of Medicines (EDQM)
API assessment by, 244
CEP issued by, 144
European Eye Banking Association (EEBA), 337
European Federation of Pharmaceutical Industries and Associations (EFPIA)
codes of conduct, 104–105
falsified medicines legislation, 123t
product distribution, 106–107, 111
European Generics Medicines Association (EGA), 243
European Initiative for Paediatric Formulations (EuPFI), 100
European Medicines Agency (EMA)
accelerated access initiatives, 159–164
early access initiatives, 88–89
EUnetHTA collaboration, 88–89, 88f
falsified medicine defined, 121
HTA parallel consultation, 88
marketing recommendation for medicinal products, 142–143
regulatory authorities, pharmaceutical quality, 229
European Medicines Verification Organisation (EMVO), 131
European Medicines Verification System (EMVS), 131
European Network for HTA (EUnetHTA)
EMA collaboration, 88–89
HTA assessments, 78–88
MAA evaluation, 50, 65–67
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), 309–310
European Pharmacopoeia (Ph. Eur.), 237
European Public Assessment Report (EPAR), 147, 262–263
European Society of Human Reproduction and Embryology (ESHRE), 337
European Transplant Coordinators Organisation, 337
European Union (EU)
medical product regulatory bodies, 205–206
pricing and reimbursement, 61–76
European Union Reference Dates (EURD)
active substances, 252
PSURs and PSUSAs scheduling, 224, 309
exceptional circumstances
medicinal product registration, 210–211
for orphan designation products, 384–385
expedited evaluation programs
ATMPs, 317t
decision tree for pathways, 318f
External Reference Pricing (ERP)), 63, 64f

F
facility requirements for medicinal products, 169
Falsified Medicines Directive (FMD), 121–134
active substance GMP, 128
active substances and excipient definitions, 128t
combination therapies, 132
companion diagnostics, 132
defining, 122
detection and management goals of, 132
EMVS in, 131–132
examples of SFFC medicines, 126
falsified active substances in routes in supply chain, 125f
harmonisation of regulation, 124
implementation of, 124–125
implementation process for, 128–129
implications and challenges of, 129–131
initiatives relevant to, 129t
key term definitions, 124t
online logo requirements, 128f
problem scope, 122
stakeholder requirements, 124
stakeholder requirements under FMD, 127t
third countries requirements under, 125, 128, 129t
unique product identifiers and information flow, 131f
first-in-human (FIH) trials guidance documents, 186
fixed-combination application, 156
follow-up referral, 156
Food and Drug Administration (FDA)
collaboration on paediatric products, 100
PSA for MAA/EMA meetings, 49
France
advertising preapproval, 111
HTA in, 82t–83t, 85f
pricing/reimbursement procedures, 68–69
pricing/reimbursement-HTA assessment competent authorities, 68
Universal Health Coverage Act CMU), 67

G
gene therapy medicinal products (GTMPs)
clinical development, 330
decision tree for classification, 323f
intended use and manipulation criteria, 325
manufacturing process, 325–327
preclinical development, 328–329
generic medicinal products, 241–256
advertising and promotion, 253
biosimilar applications, 247
biosimilar medicines, 244
comparison with innovator medicines and reference products, 241–242
compendial monographs for, 244
dossier requirements for, 247–250
electronic submission of information for, 254
GCP for, 254
GDP for, 253–254
GLP for, 254
GMP for, 253–254
Good Pharmacovigilance Practices for, 250
International regulations for, 250
labelling and package leaflet, 252–253
legal basis for generic application for MA, 245–247,
245t
manufacture and importation for, 252
postauthorisation surveillance of, 244
PSURs for, 251–252
RMP for, 251
supervision and sanctions for, 254–255
WHO definition of, 241
wholesale distribution of, 253
generic/Abridged application, 153–154
genetically modified organisms (GMO)
GTMPs, 327
vector use in, 361–362
genotoxicity studies, 167
Germany
competent authorities for pricing/reimbursement and HTA, 69
Gesetzliche Krankenversicherung (GKV), 69
HTA in, 82t–83t, 86f
medicinal product pricing under AMNOG, 70f
pricing/reimbursement procedures, 69–71
glossary, 447–465
Good Clinical Practice (GCP)
biological product guidance, 354
biosimilar clinical comparability demonstration for, 260–261
biotechnology-derived products, 280
in drug life cycle, 228
for generic medicinal products, 254
legal framework and, 234–235
Good Distribution Practice (GDP)
in drug life cycle, 228
for generic medicinal products, 253–254
inspections for, 235
Good Laboratory Practice (GLP)
ancillary quality system components, 170
for biosimilar medicinal products, 260
biotechnology-derived products, 280
definition, 165
in drug life cycle, 228
facility requirements, 169
for generic medicinal products, 254
inspections and compliance, 171
medicinal product requirements, 166
pharmacokinetic studies in vitro, 166–167
pharmacology safety studies, 166
preclinical studies required by, 166–167
products covered, 168
purpose and relevance guidance, 170–171
Quality Assurance programme, 169
regulations and guidelines for, 166
reporting study results, 170
revisions for harmonisation, 171–172
SOPs for test facility, 170
study performance, 170
test and reference items
characterization, 169–170
receipt, handling, sampling and storage, 169
test facility organisation
management, 168
principal investigator, 169
study director, 168–169
test systems, 169
in vivo feasibility and dose testing under, 167
Good Manufacturing Practice (GMP)
biotherapy-derived products, 280
certificate, 119, 233, 254–255
in drug life cycle, 228
for generic medicinal products, 253–254
for herbal medicines, 274
MAH compliance, 119
Good Pharmacovigilance Practices (GVPs)
for biosimilar medicinal products, 264–265
in drug life cycle, 228
for generic medicinal products, 254
GVP overview and modules, 303–313, 303t
MA maintenance, 224
Module I: PV systems and quality systems, 303–304
Module II: PV system master file, 304
Module III: PV inspections, 304–306
Module IV: PV audits, 306–307
Module IX: signal management, 310–311
Module V: risk management systems (RMS), 307
Module VI: adverse reaction management/reporting, 307
Module VII: PSURs, 307–309
Module VIII: post authorisation safety studies, 309–310
Module X: additional monitoring, 311–312
Module XV: safety communications, 312
Module XVI: risk minimisation measures, 312–313
nonprescription medicinal products, 273
H
harmonisation
EURD in, 252
GLP regulations, 171–172
medical device regulation, 24–25
of SmPC, 206, 209
Heads of Medicines Agencies (HMA), 175
health monitoring measures for public health, 117
Health Problem and Current use of Technology (CUR) HTA model, 80
Health Technology Assessment (HTA), 77–92
comparison in EU countries, 81–84, 83t
decision timeline, 87t, 88f
EMA and EUnetHTA collaboration, 88
harmonisation, 84–88
HTA in Member States, 82t
legal framework, 77–78
models used for: CUR, 80
models used for: ECO, 80
models used for: EFF, 80
models used for: ETH, 80–81
models used for: LEG, 81
models used for: ORG, 81
models used for: SAF, 80
models used for: SOC, 81
models used for: TEC, 80
organisation and structure in EU, 81–84
parallel advice for MAA, 49–51
pricing and reimbursement, 65–66
role in decision making, 84
role in product market, 78–80
herbal medicinal product MAA, 156
human blood or plasma products, 365–374
batch-release requirements, 371
CHMP working groups, 368
Council of Europe publications on, 369
donation testing for, 369–370
guidelines and documents for, 369–370
legal framework, 368–369
marketing authorisation dossier for, 370–371
plasma master file, 371
plasma-derived medicinal products, 366–367, 367t
postmarketing pharmacovigilance for, 371
registration procedures for, 369
Single European Code structure, 340t
transition to new regulations, 371–372
TSE safety evaluation, 370
virus safety evaluation, 370
Human Organ Transplantation Directive, 349
human tissue products, 335–351
\textit{ATMP} classification, 341
classification of, 341–342
contiguous legislation, 348–349
distribution and import, 340
donation of, 338
donor selection and testing, 338–339, 339t
\textit{EUTCD} requirements, 337–338
legislation on, 337–338
licensing and inspections, 342
MA authorisation for, 344
MA procedure for, 344
as medical device, 347
pharmacovigilance (PV), 341–342
processing and storage, 339–340
procurement, 338
quality system for establishment and responsible person, 342–343
registration, 337, 344–348
regulatory framework for, 348t
responsible person qualifications/responsibilities, 343t
tissue establishments and banks, 342
traceability, 340–341
hybrid applications, 155

I
Identification of Medicinal Products (IDMP), 223
immunogenicity data
advanced therapy medicinal products, 329
biosimilar medicinal product development, 259
biotechnology-derived products, 281–283
comparability exercise for biosimilars, 260–262
pre-licensing product testing, 213
vaccines, 358, 360
immunotoxicity studies, 167
Impact on Clinical Research of European Legislation (ICREL), 174
Importing Directive, 349
in vitro diagnostic (IVD) medical device regulations, 26
In Vitro Diagnostic Regulation (EU IVDR), 390
influenza vaccines, 358–360, 359f
Information and Work Sharing projects, 250
informed consent applications, 156
innovator medicines (originator products), 242–243
inspection process
in drug approval process, 231f
EudraGMDP database entries, 233
GLP regulations, 171
Medicines and Healthcare products Regulatory Agency (MHRA), 236–237
pharmaceuticals, 230–233
tissue establishment inspections, 342
installation qualification (IQ), 170
international birth date (IBD), 197
International Coalition of Medicines Regulatory Authorities (ICMRA), 238–239
International Conference on Harmonisation (ICH)
coordination and cooperation enhancement, 117
Development Safety Update Report, 176
guidelines for biotechnology-derived products, 280–281
harmonisation of preclinical testing, 166
pharmaceutical quality systems, 229
PSUR format revision and scheduling, 309
International Federation of Pharmaceutical Manufacturers Association (IFPMA)
code of ethics, 103, 105, 107
promotional material approval, 111
International Generic Drug Regulators Pilot (IGDRP), 250
International Medical Device Regulators Forum (IMDRF)
Index

coordination and cooperation enhancement, 117

International Medical Products Anti-Counterfeiting Taskforce (IMPACT), 122, 123t

International Society of Pharmacoepidemiology (ISPE), 238, 309

Investigational Medicinal Product Dossier (IMPD)
biological product guidance, 354
content requirements for, 354
submission, 194–195

investigational medicinal products (IMPs), 181

Clinical Trials Directive definition of, 179
clinical trials for, 174
CTD information in dossier, 194
documentation requirements for, 354
DSURs for, 196
for FIH trials, 186
GMP requirements for, 195
manufacturing requirements for, 362
risk-benefit amendment notification, 186
SUSARs/DSURs for, 196

Italian Farmaindustria Code, 106

Italy
advertising preapproval, 111
competent authorities for pricing/reimbursement and HTA, 72
HTA in, 82t
pricing/reimbursement procedures, 72–73
Servizio Sanitario Nazionale, (SSN), 72

J
Joint Action on Market Surveillance (JAMS) 3, 116
Joint Immediate Action Plan, 118

L
labelling requirements: combination products, 397
Legal Aspects (LEG) HTA model, 81
legal framework/legislation
for adaptive and alternative pathways, 160–162
Advanced Therapy Medicinal Products (ATMPs), 315–334, 344
ATMP Regulation, 317–320
clinical trial improvements, 176f
clinical trials, 175
comparative matrix of legislation, 399–446
herbal medicinal products, 273–274
human blood or plasma products, 368–369
human tissue products, 337–338
MAA, 32–34
mechanism for medicinal products for human use, 18–19
medical product, 18
orphan medicinal products, 376
pharmacovigilance (PV), 302–303
product legislation, 17–18
lifecycle of drugs
regulations in, 228f
research and development (R&D), 22–23
local tolerance studies, 167

M
Marketing Authorisation Application (MAA)
accelerated assessment for, 35
approval types, 34, 36t
for biosimilar medicinal products, 261–262
for biotechnology derived products, 156
clarification and discussion meetings, 54–55
communications to EMA, 41–52
dossier quality section, 144
EMA meetings during review, 53–60
EU format and content of, 144
human–veterinary variations, 20–21
legal basis and dossier requirements, 32–34
legal basis for generic application for MA, 245–247
medicinal product application types, 153–156, 154t, 155–156
for medicinal products, 143–148
PIP requirements, 94–95, 98–100
prior EMA meetings for, 41–52
procedural steps and EMA meetings, 42–47
procedure timelines for, 55f, 57f
procedures for, 34–35
scientific advice and protocol assistance, 37–38
Scientific Advice review, 54
Scientific committee role in review, 53, 54t

Marketing Authorisation Holder (MAH)
advertising to general public, 108
advertising to healthcare professionals, 105
definition of, 143
EMVO, 119
GMP compliance, 119
MA maintenance, 223
obligations for medicinal products, 146, 148, 153
paediatric products, 99–100
PIP preparation, 94–95
product failure responsibility and liability, 206
renewal date agreement with Reference Member State, 288
responsibilities and obligations for medicinal products, 143–144
role in various application types, 156
scientific service implementation, 111
submission of information for generic products, 254
worksharing, 223

Marketing Authorisation (MA)
adaptive and alternative pathways, 159–164
for generic medicinal products, 255
human tissue products, 344
regulatory strategy for, 138
**maximum tolerated dose (MTD)**, 166
MEDDEV guidance documents: revisions and updates, 118
**Medical Device Coordination Group (MDCG)**
borderline combination products, 391
regulatory classification determination, 391, 394–395, 397
regulatory strategy development, 138
regulatory strategy information, 138
**medical device legal system**
adaptive and alternative pathways, 162
development, 25–26
enforcement, 117
enforcement and competent authorities, 117–118
market surveillance, 117–118
regulation evolution and harmonisation, 23–25
**medical device legislation and classification: human tissue/cell products**, 347
**Medicinal Product Directive (MPD)**, 18, 32
**medicinal products for human use**
adaptive and alternative pathways, 160–162
bibliographic applications/well-established use, 155–156
clinical trials for, 173–204
Complete/Full and Independent, 153
decentralised procedures, 154t
enforcement, 119–120
enforcement and competent authorities, 117–118
factors affecting pricing, 62f
fixed-combination application, 156
generic/Abridged, 153–154
herbal medicinal products, 156
hybrid applications, 155
informed consent applications, 156
legislation in EU, 18–19
Marketing Authorisation Application, 153–156
mixed marketing, 156
**medicinal products MAA applications**
bibliographic applications/well-established use, 155–156
Complete/Full and Independent, 153
decentralised procedures, 154t
fixed-combination application, 156
generic/Abridged, 153–154
herbal medicinal products, 156
hybrid applications, 155
informed consent applications, 156
mixed marketing, 156
**Medicines and Healthcare products Regulatory Agency (MHRA)**, 236–237
**Medicines for Europe**, 243
**Member States**
clinical trial authorisation procedures in, 188
clinical trial safety procedures, 187
competent authorities marketing guidelines, 142–143
enforcement by competent authorities, 115–120
GLP regulations in, 166
Marketing Authorisation Application in, 19
**mixed marketing**, 156
**Mutual Acceptance of Data (MAD) system**, 166, 234
**Mutual Recognition Agreements (MRAs)**
for generic product GMP inspections, 243–244
for inspections, 235
**Mutual Recognition Facilitation Group (MRFG)**, 150
**Mutual Recognition Procedure (MRP)**
application format for, 145
authorisation of medicinal products, 149–151
biosimilar medicinal product registration, 245
biotechnology-derived product marketing authorisation, 277
comparison of pathways for nonprescription products, 270f
criteria for use of, 19, 149
evaluation of products, 14
flowchart for, 151f
for generic products, 245
human blood/plasma postmarket pharmacovigilance, 371
MAA procedure with, 221f
medicinal product registration, 205
for medicinal products, 151t
multiplication/duplication of applications, 153
nonprescription products, 269
phases and timeline for medicinal products, 149–151
postauthorisation requirements for biotechnology products, 288–289
product registration, 220–221
Reference Member State selection, 151–152
registration for human blood/plasma products, 369
registration for medicinal products, 153, 209, 220
regulatory dossier assessment, 220–221
submissions and Reference Member State role and timeline, 150–151
**mutual recognition/decentralised procedure referral**, 157

**N**
national authorizations, medicinal products, 153
**national competent authorities**, 115–120
action on medical device safety, 117–118
application for clinical trial authorisation, 184–187
clinical trial application, 185t
cooperation and coordination for enforcement, 116–117
coordination and cooperation enhancement, 117
generic medicinal product safety, 254–255
inspection process, 230
medical devices, 117
national regulatory bodies, 116
pharmaceutical quality and inspections, 229–233
pricing and reimbursement and HTA, 230
tissue establishment inspections, 342
National Medicines Regulatory Authorities (NMRA), 130
National Medicines Verification Organisations (NMVOs), 132
National Procedure
biosimilar medicinal product registration, 261
comparison of pathways for nonprescription products, 270f
generic medicinal products, 245
human blood/plasma products, 369
MAA procedure with, 221f
marketing authorisation for medicinal products, 19
medical product registration, 209–210
medical product registration, 221
nonprescription medicinal products, 269
product registration, 209–210, 220–221
regulatory dossier assessment, 221
variability of, 149
new chemical entity (NCE): preclinical test plan, 166
noninvestigational medicinal products (NIMPs)
derived, 179
SUSARs for, 196
nonprescription medicinal products, 267–276
advertising and promotion, 272–273
advertising to general public, 273
common uses of, 269t
definition of, 268
herbal medicinal products, 273–274
legal basis of MAA, 269
legislation of, 268
marketing access pathways for, 268–269, 270t
pharmacovigilance and safety reporting, 273
product information and labelling, 269–271
reclassification from prescription to, 271–272
role in self-care, 268
successful switch strategy for, 272
warning statements and guidance for, 271
Notified Bodies: responsibilities of, 118

O
office based evaluation and risk assessment (OBERA), 235
Official Control Authority Batch Release (OCABR)
batch-release requirements, 357
EDQM procedures for, 368
plasma products, 371
Official Medicines Control Laboratories (OMCL)
blood/plasma product testing, 368
postmarketing lot release, 357
vaccine testing by, 354
operational qualification (OQ), 170
Oral Explanation (OE) meeting, 55
Organisation for Economic Co-operation and Development (OECD)
EMA collaboration, 10
GLP guidelines, 191, 239, 254
harmonisation of preclinical testing, 166–168
mutual acceptance of data system, 234
Organisational Aspects (ORG) HTA model, 81
Orphan Drug Act, 375
Orphan Medicinal Products (OMP) Regulation
COMP established by, 377–378
product designation procedure, 381
significant benefit concept in, 382–383
similar medicinal product and clinical superiority in, 383
orphan medicinal products (OMPs), 375–388
annual report requirement, 380
application evaluation and timetable for, 379
conditional marketing authorisation for, 384
designation expiry, 381
designation procedure application, 378–379
designation request content, 381–382
EU laws and regulations, 38
European Commission decision, 379–380
harmonisation efforts, 376
incentives for development, 376–377
legal framework, 376
MAA for designation product, 382–384
medical plausibility for request and prevalence, 382
orphan designation benefits, 206
orphan designation benefits and criteria, 8, 38, 376, 380f
parallel applications, 379
pathways for expedited development and approval, 384
significant benefit concept in, 382–383
similar medicinal product and clinical superiority in, 383
sponsorship transfer, 381
over-the-counter (OTC) medicines: advertising to general public, 108

P
Paediatric Committee (PDCO), 95, 207
Paediatric Investigation Plan (PIP)
Marketing Authorisation Holder, 94–95
submission procedures in, 97–99, 98f
paediatric product regulation
application procedure, 97–99
background and scope, 93–94
compliance check, 99
deferrals, 96–97
Marketing Authorisation Holder, 99–100
PDCO, 95
PIPs, 94–95
population and product definitions, 94
product development under, 100–101
research incentives, 99
waivers, 95–96

**Paediatric Regulation**, 93–94
**Paediatric Use Marketing Authorisation (PUMA)**, 94
**Parallel Scientific Advice (PSA)**, 49
**Patients and Social Aspects (SOC) HTA model**, 81
**Periodic Benefit-Risk Evaluation Report (PBRER)**
- EU format for, 307
- format for, 307, 308t
- ICH guideline for, 309
**Periodic Safety Update Report (PSUR)**
- benefit-risk balance, 251–252, 265, 289–290, 313
- for biosimilar medicinal products, 265
- frequency of, 280
- MAH submission of, 307
- postmarketing safety assessment, 289, 292–293
- PSUR format revision and scheduling, 309
- renewal procedures and, 300
- requirements for, 304
- RMP update, 311
- sharing through Eudamed, 118
- submission and review process for, 224
- submission of, 307–309
- submission to EMA, 217
- synchronization with other reports, 197, 290, 309
- validated signals in, 311
**Periodic Safety Update Single Assessment (PSUSA)**
- submission, 217

**pharmaceutical directives**
- ATMPs, 21–22
- codification/clarification, 19
- development of regulatory system, 20
- human–veterinary MAA variations, 20

**Pharmaceutical Inspection Convention (PIC)**, 117, 237

**Pharmaceutical Inspection Co-operation Scheme (PIC/S)**
- for generic products, 243–244
- participants in (list), 237–239

**pharmacodynamic (PD) testing: biosimilars**, 259
**pharmacokinetic (PK) testing for biosimilar medicinal products**, 259

**pharmacovigilance (PV)**
- EC definition and development of, 302
- fees, 313
- GVP overview and modules, 303t

**human tissue products, 341–342**
**ICSR expedited submission requirements**, 309f
**legal framework, 302–303**
**notification of withdrawn products, 313**
**risk management plan modules, 308t**
**signal management lifecycle, 311f**
**system master file (PSMF) contents, 305f**
**vaccines, 357**

**Pharmacovigilance Regulation, 357**

**Pharmacovigilance Risk Assessment Committee (PRAC)**
- communications, 56
- coordination and cooperation enhancement, 117
- MA maintenance, 224
- MAA review, 53–54, 54t

**photo-safety testing, 167**

**Plasma Master File (PMF)**, 144

**plasma master file (PMF)**, 144, 371

**postauthorisation requirements (pharmaceutical)**
- annual re-assessment
- assessment procedures, 295
- dossier requirements for, 294–295
- for biotechnology-derived products, 288–289
- centrally approved product renewal
- assessment procedure, 293–294
- dossier requirements for, 290
- legal framework for, 285, 288–289
- major changes/extension application, 299
- MRP/DCP product renewal, 288–289
- assessment procedures, 290
- dossier requirements for, 289
- other postauthorisation measures and enforcement, 295
- re-examination, 294
- vaccines, 356–357
- variation assessment and notifications, 297–299
- variation dossier requirements, 295–297

**postauthorisation safety studies (PASS)**, 188
- for biosimilar medicinal products, 265

**postmarket clinical follow-up (PMCF)**, 162

**postmarket surveillance (PMS)**
- for generic medicinal products, 244
- manufacturer, 117–118

**postmarket surveillance requirements: combination products**, 397

**Potential Serious Risk for Public Health (PSRPH)**, 209

**preclinical testing**
- GLP regulations in, 165
- OECD GLP principles, 167–168

**preliminary assessment report (Pr/AR) and RMS**, 219–220

**Prescription Medicines Code of Practice Authority (PMCPA)**, 111
pricing and reimbursement, 61–76
  containment policies of Member States, 67f
current trends, 67
economic evaluations, 66, 66f
factors affecting pricing for medicinal products, 61–62
legal framework, 62–63
link between models and HTA, 67–74
models and HTA case studies, 67–74
models for, 64
cost-based pricing, 63–64
reference-based, 63, 65t
value-based pricing, 64
pricing factors for, 62f
reference pricing system for generic products, 241–242
reimbursement, 65–67
vaccines, 362
primary mode of action (PMOA), combination products, 390–391
PRIME (PRIority MEdicines)
  HTA/EMA collaboration for, 89
  laws and regulations, 36–37
Q
Qualified Person (QP/QPPV)
generic medicinal products, 253
GMP certification, 195
for human tissues/ATMPs, 343t
pharmacovigilance (PV), 303
pharmacovigilance for medicinal products, 144
postmarket pharmaceutical compliance, 290–291
PSMF and, 251
in recall decisions, 119
signal management, 310
tissue establishment, 343
vaccine development, 354
vaccine release, 354
Quality Assurance (QA) programme: GLP requirements, 169
Quality Management System (QMS)
  assessors and inspector relationship in, 228–229, 229f
  in clinical trial protocol, 194
for combination products, 396–397
conformity assessment in, 136
human tissue products regulation, 337
ICH QMS requirements, 229
pharmacovigilance factors for, 304
PMS requirements, 118
postmarket surveillance in, 117–118
regulatory strategy for, 138
quality review of documents (QRD)
labelling templates, 271, 279
medicinal product authorisation procedures, 145, 215, 222
SmPC information requirements, 252, 312
templates in Centralised Procedure, 279
quality systems and inspectorate process
  assessors and inspector relationship in, 229f
British Pharmacopoeia (BP), 237
EDQM inspection process, 233
Eurasian Economic Union, 238
European Pharmacopoeia (Ph. Eur.), 237
GCP inspections, 234–235
GDP inspections, 235
for generic medicinal products, 254
GLP inspections, 234
GMP inspections, 231–233
GMP/GDP Inspectors Working Group, 234
ICMRA, 238
industry associations, 238
joint inspection program participants, 236–237
legal framework for, 230, 230f
list of other agency inspections, 235
MRAs for inspections, 235
OECD, 239
pharmaceutical regulation evolution, 227–228
pharmacopeial compendia, 237
PIC/S, 237
requirements for EU, 229
Swiss Pharmacopoeia (Ph. Helv.), 237
Quality-Adjusted Life Years (QUALYs)
in HTA assessment, 84
in pricing and reimbursement, 66
R
reference medicine, 241
pharmacopeial compendia for API, 244
Reference Member State (RMS)
business validation and checklist for, 218
DCP role of, 219–220
Decentralised Procedure applications role and timeline, 151–152
decentralised procedure role, 208
follow-up referral, 156
initial product assessment, 206
MAA evaluation, 19
MAA presubmission meetings, 211
mutual recognition and decentralised procedure referrals, 157
Mutual Recognition Procedure (MRP), 209, 220–221
Mutual Recognition Procedure phase 2 timeline, 150
Mutual Recognition Procedure role, 150
PrAP from, 219
renewal date agreement with MAH, 288
selection for MAA, 149
selection of, 200
worksharing for MA maintenance, 223
reference-based pricing model, 63, 65t
referrals
  community interest referral, 157
  divergent decision referral, 157
  European community referral, 156
  follow-up referral, 156
  generic medicinal product evaluation, 245
  mutual recognition/decentralised procedure referral, 157
registration of medicinal products, 205–226
  accelerated assessment, 211
  adaptive pathway, 210
  ASMF for, 214
  bibliographic applications/well-established use, 213
  biosimilar medicinal products, 261–263
  of biosimilar medicinal products, 261–263
  for biotechnology-derived product, 278–279
  for biotechnology-derived products, 278–279
  Certificate(s) of Suitability, 216
  combination products, 390
  conditional approval, 210
  conditional authorisation, 210
  content of submissions, 215, 215t
  eCTD envelope and CTD format, 215–216
  exceptional circumstances, 210–211
  fixed combination, 213
  full registration, 212
  generic products, 255
  generic registration, 212
  for human blood or plasma products, 369
  hybrid registration, 212
  informed consent, 213
  MA maintenance, 223–224
  MAA application types, 211–214
  MAH liability and, 206
  materials of human/animal origin, 216
  mixed marketing, 214
  orphan medicinal products, 206–207
  other documentation, 222–223
  paediatric investigations, 207–208
  presubmission meeting request, 211
  procedure types, 208–209
  PSURs and PSUSAs, 224
  questions on dossier, 222
  referrals, 224
  regulatory dossier changes/variations, 223
  regulatory dossier submission, 216–217
  regulatory dossier validation, 217–218
  routes for, 369
  scientific advice, 207
  scientific advice application, 214–215
  similar biological registration, 212–213
  urgent safety restrictions, 224
Regulation in legal framework, 230
regulatory authorities
  Council of Europe, 229
  EMA, 1–5, 7–10
  European Commission (EC), 229
  European Medicines Agency (EMA), 229
  European Medicines Regulatory Network, 5–7
  Task Force for Relations with the United Kingdom (UKTF), 228, 230
regulatory dossier
  for blood/plasma products, 370–371
  Centralised Procedure, medicinal products, 218
  changes/variations for medicinal products, 223
  Decentralised Procedure (DCP), medicinal products, 219–220
  Mutual Recognition Procedure (MRP), medicinal products, 220–221
  National Procedure, medicinal products, 221
  submission for medicinal products, 216–217
  validation for medicinal products, 217–218
regulatory information resources
  core SmPC guidance for vaccines, 360
  Council of Europe publications on blood/plasma products, 369–370
regulatory strategy
  confirming strategy, 138–139
  developing and implementing, 136–138
  documentation of, 138–139
  information resources for development, 138
  key questions during development, 137t
  market considerations in, 135–136
  prescription to nonprescription strategy, 272
  review/update of, 139
Reporting Member State
  clinical trial authorisation process, 175, 188–190
  low-intervention clinical trial determination, 193
reproductive studies, 167
responsible person (RP)
  generic products, 250
  tissue quality systems, 342–343, 343t
risk management plan (RMP), 289
  adaptive pathways and, 210
  for Advanced Therapy Medicinal Products (ATMPs), 330–331
  for ATMPs, 330–331
  generic medicinal products, 251
  pharmacovigilance modules, 308t
  requirements for, 304
S
  Safeguard Clause for devices, 117
  Safety (SAF) HTA model, 80
safety measures in clinical trials, 187
scientific advice and protocol assistance
Index

for MAA, 37–38
review before EMA meeting, 48
Scientific Advice Working Party (SAWP), 37
Scientific Advisory Group (SAG) meeting, 55–56
scientific committees (EMA): MAA review, 53, 54t
serious adverse events (SARs) for IMPs and NIMPs, 196
Single European Code (SEC), 340t, 349
software with medical devices, 26, 391
somatic cell therapy medicinal products (sCTMPs)
clinical development, 329–330
intended use and manipulation criteria, 324–325
manufacturing process, 326
preclinical development, 327–328
Spain
competent authorities for pricing/reimbursement and HTA, 71
HTA in, 82t–83t
National Health Service (SNS), 71
pricing/reimbursement procedures, 71–72
Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) medicines, 121, 126, 129t, 132
Standard Assessment Review Timeline: MAA review, 55f
Standard Operating Procedures (SOPs), 170
Summary of Product Characteristics (SmPC)
advertising and promotion compliance, 104–107, 109
changes affecting safety, 224, 263–265, 288–289, 296
generic and reference products, 33, 243, 246–247
human blood or plasma products, 368
as IMPD, 195
in MAA, 35
medicinal product MA maintenance, 143–144, 150–153, 156
national competent authority product authorisation, 184
product labelling, 252, 271, 291
QRD review, 222–223
for vaccines, 355–356, 360
Supplementary Protection Certificate (SPC)
paediatric investigation incentives, 208
paediatric medicinal products, 94
protection of innovator medicine by, 243
suspected unexpected serious adverse reactions (SU-SARs)
electronic reporting, 182
reporting, 196–197
Swiss Pharmacopoeia (Ph. Helv.), 237

T
therapeutic interchangeability of biosimilars, 22, 263
tissue-engineered products (TEPS)
clinical development, 330
decision tree for classification, 322f

intended use and manipulation criteria, 325
manufacturing process, 327
preclinical development, 329
toxicity studies
for biosimilar medicinal products, 259
preclinical testing, 166
traceability: SEC for tissues/ATMPs, 349
Traditional Herbal Medicinal Product Directive (THMPD), 273–274
traditional herbal medicinal products: regulation evolution, 23
Transmissible Spongiform Encephalopathy (TSE)
biotechnology-derived products, 281–282
blood and plasma evaluation for, 15, 370
Transparency Directive, 17, 62–63, 362
Treaty on the Functioning of the EU, 62

U
unique device identifiers (UDI), 138, 349
United Kingdom (UK)
advertising and promotion, 111–112
assessors and inspector relationship in, 228–229
Brexit effects for quality management, 228–229
competent authorities for pricing/reimbursement and HTA, 73
HTA in, 82t–83t
implementation of ECTR in, 179
National Health Service (NHS), 73
pricing/reimbursement procedures, 73–74
United States (US) GLP regulations in, 166
Urgent Safety Restriction (USR)
biosimilar medicinal products, 264
dossier requirements for, 290
timeframe for implementation, 296–297
variation classification and, 300

vaccine adverse event reporting system (VAERS), 357
Vaccine Antigen Master File (VAMF)
development processes for, 355–356
EU regulations, 21
veterinary vaccines, 23
vaccines, 353–364
adjuvants in, 360–361
classification and development pathway, 353–354
clinical studies, 356
CTA for, 354–355
DNA and therapeutic vaccines/GMO-based, 361–362
GMO-based vaccines, 361–362
guidance on, 360
immunomodulators in, 361
licensure, 356–362
Index

lot release, 356
manufacturing process, 354–355
nonclinical studies, 355–356
overview, 362
pandemic influenza, 360
pharmacovigilance (PV), 357
prepandemic influenza vaccines, 360
pricing and reimbursement, 362
seasonal influenza vaccines, 358–359, 359f
for special populations, 358
vaccines, 356–357
VAMF, 355
VAMF certification, 355t
VAMF certification and requirements, 21
vector use in, 361

value-based pricing model, 64
veterinary medicinal products
  CMDv, 18
  CVMP role in authorisation, 8
  GMP inspections for, 237–238
  national competent authorities for, 6–7
  OMCLs testing, 368
  pharmaceutical regulation evolution, 22–23
  regulatory agencies for, 2–5, 229–230
  regulatory principles, 22–23
  scientific advice and protocol assistance, 48
  variations to MAAs, 20–21

viral clearance, 282

Voluntary Harmonization Procedure (VHP)
  CTFG and, 200
  implementation and guidance for, 177

W
worksharing in market authorisation maintenance, 223

World Health Organization (WHO)
  falsified medicine initiative/IMPACT, 122
  generic medicinal product definition, 241
  Global Surveillance and Monitoring System (GSMS), 130
  HTA definition by, 66
  International Clinical Trials Registry Platform (WHO ICTRP), 199
  paediatric medicine initiative, 100
  pandemic vaccine development and, 360
wrongly affixed CE-marking, 117